FDA Expedites Review for Pancreatic Cancer Drug ERAS-0015

The FDA has granted Fast Track Designation to Erasca's ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic adenocarcinoma. This designation aims to accelerate the development and review of the therapy due to the urgent need for new treatments for this serious condition, supported by promising Phase 1 trial data.